Response to Comments on "Aluminium Adjuvants in Vaccines and Potential Health Effects: Systematic Review"

Why It Matters

Clarifying the evidence base protects public confidence and guides regulators on the safety profile of aluminium‑containing vaccines, a cornerstone of modern immunisation programs.

Key Takeaways

• Systematic review found no causal link between aluminium adjuvants and adverse events
• Joura 2015 trial confounded by differing antigens, not just aluminium
• Danish cohort used dose‑response analysis, reducing selection bias
• Observational studies remain vital for detecting rare or delayed vaccine harms
• Ongoing pharmacovigilance and transparent reporting essential for vaccine safety

Pulse Analysis

The debate over aluminium adjuvants resurfaced after a rapid response challenged a recent BMJ systematic review. The review, which screened human studies up to November 2025, concluded that the collective evidence does not support a causal relationship between aluminium exposure from vaccines and serious neurological outcomes. By applying predefined selection criteria and a structured risk‑of‑bias assessment, the authors aimed to synthesize findings across randomized trials, cohort studies, and regulatory data, offering a comprehensive safety portrait that individual studies alone cannot provide.

Critics cited the Joura 2015 HPV vaccine trial and a 2020 systematic review of HPV vaccine harms, but the authors point out key methodological shortcomings. The Joura trial compared Gardasil 9 with Gardasil, differing not only in aluminium content but also in antigen composition and dosing, making it impossible to attribute any effect solely to aluminium. Likewise, the 2020 review’s analyses of postural orthostatic tachycardia syndrome and nervous system disorders were deemed exploratory, with trials not designed to assess harms. In contrast, the Danish nationwide cohort employed a dose‑response framework that mitigated selection bias, strengthening the inference that aluminium exposure at typical vaccine levels is not linked to chronic disease.

These clarifications have practical implications for health agencies and clinicians. Robust systematic reviews inform regulatory decisions, vaccine policy, and public communication, especially when misinformation circulates. Continued pharmacovigilance—leveraging large‑scale observational data, transparent reporting, and periodic evidence updates—remains essential to detect rare or delayed adverse events. By emphasizing methodological rigor and ongoing surveillance, the authors reinforce confidence in aluminium‑adjuvanted vaccines while acknowledging the need for vigilant, evidence‑driven oversight.